Skip to main content

Tobacco Use

0
Pipeline Programs
5
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
3 programs
Click City®: TobaccoN/A1 trial
Referral to QuitlineN/A1 trial
Support2Quit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation TipsN/A1 trial
Active Trials
NCT03682900Completed2,673Est. Jun 2022
NCT05612152Unknown1,600Est. Jul 2024
NCT05797155Completed437Est. Mar 2025
Century Therapeutics
Century TherapeuticsPHILADELPHIA, PA
3 programs
Non-Menthol Very Low Nicotine CigarettesN/A1 trial
VLN cigarettesPHASE_11 trial
VLN menthol cigarettesPHASE_11 trial
Active Trials
NCT03571724Completed142Est. Mar 2019
NCT03559751Completed66Est. Sep 2018
NCT03559725Completed55Est. Oct 2018
Alliance Pharmaceuticals
1 program
TrainingN/A1 trial
Active Trials
NCT03040349Unknown300Est. Dec 2019
Pfizer
PfizerNEW YORK, NY
1 program
TrainingN/A1 trial
Active Trials
NCT03556774Unknown2,200Est. Aug 2021
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
varies by projectN/A1 trial
Active Trials
NCT01323023Completed4,463Est. Jan 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Century TherapeuticsVLN menthol cigarettes
Century TherapeuticsVLN cigarettes
Oregon TherapeuticsSupport2Quit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips
Oregon TherapeuticsReferral to Quitline
Oregon TherapeuticsClick City®: Tobacco
PfizerTraining
Century TherapeuticsNon-Menthol Very Low Nicotine Cigarettes
Alliance PharmaceuticalsTraining
Colorado Therapeuticsvaries by project

Clinical Trials (9)

Total enrollment: 11,936 patients across 9 trials

NCT03559725Century TherapeuticsVLN menthol cigarettes

Evaluation of Abuse Liability of Very Low Nicotine (VLN) Mentholated Cigarettes

Start: May 2018Est. completion: Oct 201855 patients
Phase 1Completed
NCT03559751Century TherapeuticsVLN cigarettes

Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes

Start: Apr 2018Est. completion: Sep 201866 patients
Phase 1Completed
NCT05797155Oregon TherapeuticsSupport2Quit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips

A Mobile App Based Cognitive Dissonance Intervention for Smoking Cessation

Start: Dec 2023Est. completion: Mar 2025437 patients
N/ACompleted
NCT05612152Oregon TherapeuticsReferral to Quitline

Choose2Quit: Improving Equity in Smoking Cessation for Low Income Adults

Start: Nov 2022Est. completion: Jul 20241,600 patients
N/AUnknown
NCT03682900Oregon TherapeuticsClick City®: Tobacco

Expanding the Click City Tobacco Prevention Program to Include E-cigarettes and Other Novel Tobacco Products

Start: Oct 2019Est. completion: Jun 20222,673 patients
N/ACompleted
NCT03556774PfizerTraining

Boosting Chinese Healthcare Service Providers' Utilization of Smoking Cessation Interventions by 'WeChat WeQuit' Program

Start: Apr 2019Est. completion: Aug 20212,200 patients
N/AUnknown
NCT03571724Century TherapeuticsNon-Menthol Very Low Nicotine Cigarettes

A Study to Assess Changes in Cigarette Consumption During a Switch to Very Low Nicotine Cigarettes

Start: Jun 2018Est. completion: Mar 2019142 patients
N/ACompleted
NCT03040349Alliance PharmaceuticalsTraining

Tobacco Treatment TrAining Network in Greece & Cyprus

Start: Feb 2017Est. completion: Dec 2019300 patients
N/AUnknown
NCT01323023Colorado Therapeuticsvaries by project

A Study to Examine Health Behavior Change Strategies for Primary Care

Start: Jun 2005Est. completion: Jan 20134,463 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.